This protocol addresses splenic vein thrombosis in patients with chronic splanchnic vein thrombosis — a distinct presentation defined by long-standing disease with structural vascular changes that require a carefully individualised approach.
Chronic splanchnic vein thrombosis is generally defined by the presence of signs of long-standing thrombosis. This specific scenario involves:
Extensive intra-abdominal venous collaterals or cavernous transformation of the portal vein — anatomical hallmarks of chronic, established disease that directly shape the risk-benefit evaluation of any therapeutic intervention.
In this population, the decision to initiate anticoagulant therapy is made on a case-by-case basis. For selected patients, a watchful approach may be appropriate to minimise bleeding risk. The structured protocol specifies which anticoagulant strategies are considered and how patient selection is determined.
Chronic splanchnic vein thrombosis is generally defined by the presence of signs of long-standing thrombosis such as extensive intra-abdominal venous collaterals or cavernous transformation of the portal vein.
In patients with chronic splanchnic vein thrombosis, we recommend carefully evaluating the use of anticoagulant therapy on a case-by-case basis and considering a watchful approach in selected patients to minimize bleeding.
The main objectives of anticoagulant therapy for chronic splanchnic vein thrombosis are the prevention of recurrent thrombosis as well as vessel recanalization, although the latter tends to be less impacted by treatment compared to recanalization in patients with acute thrombosis.
View source ↗